Spinal cord stimulation at different frequencies triggers distinct endogenous opioid peptide pathways to produce pain relief, with low-frequency stimulation specifically boosting enkephalin levels.
Different frequencies, different peptidesLow-frequency (2 Hz) SCS worked via mu/kappa opioid receptors and boosted enkephalin levels, while ultra-high frequency (10 kHz) engaged all three opioid receptor types — showing the body's painkilling peptide system is frequency-tunable.
What the researchers found
The analgesic effect of SCS increased with stimulation intensity between 20% and 80% motor thresholds. All tested frequencies (2, 15, 50, 100, 10,000 Hz, and alternating 2/100 Hz) were similarly effective at reducing pain.
Critically, different frequencies operated through distinct opioid peptide mechanisms: 2 Hz SCS significantly increased methionine enkephalin in cerebrospinal fluid and its effect was blocked by mu or kappa opioid receptor antagonists. 100 Hz SCS was blocked only by a kappa antagonist. 10 kHz SCS was blocked by antagonists at any of the three opioid receptor types (mu, delta, or kappa). No tolerance developed within 24 hours of continuous stimulation.
Why it matters
Spinal cord stimulation is already used clinically for chronic pain, but programming it has been somewhat empirical. This study reveals that the device literally triggers the body's own painkilling peptide system — and that different settings activate different branches of that system. This mechanistic insight could help clinicians choose optimal stimulation parameters for individual patients, potentially improving outcomes for the millions of people living with chronic neuropathic pain without relying on opioid medications.
How the study worked
Researchers used a spared nerve injury model in rats to create neuropathic pain. They then applied spinal cord stimulation at various intensities (20-80% of motor threshold) and frequencies (2 Hz to 10 kHz, plus dense-dispersed patterns). Pain sensitivity was measured using mechanical withdrawal thresholds. To determine the opioid mechanisms involved, specific opioid receptor antagonists (for mu, delta, and kappa receptors) were administered before SCS. Methionine enkephalin levels were measured in cerebrospinal fluid using radioimmunoassay.
What this study cannot tell us
This study was conducted entirely in rats, and the neuropathic pain model (spared nerve injury) may not fully replicate the complexity of human chronic pain conditions. The 24-hour tolerance assessment is relatively short — longer-term tolerance effects remain unknown. Specific opioid peptide measurements were only performed for methionine enkephalin at 2 Hz; the peptides mediating effects at other frequencies were inferred from antagonist experiments rather than directly measured. Translation to human SCS programming requires clinical validation.
How to read the evidence
This is a well-designed preclinical animal study using pharmacological antagonist experiments to establish mechanistic pathways. The use of multiple frequencies, receptor-specific antagonists, and direct peptide measurements provides strong mechanistic evidence. However, as an animal study, direct clinical translation remains to be confirmed.
When this study was published
Published in 2022, this study addresses ongoing questions about SCS mechanisms at a time when high-frequency (10 kHz) spinal cord stimulation is gaining clinical popularity. The findings are directly relevant to current clinical practice and device development.
The bigger picture
This study bridges two major areas of neuroscience — neuromodulation technology and endogenous opioid peptide biology. At a time when the opioid crisis has intensified the search for non-drug pain treatments, understanding that SCS works by releasing the body's own opioid peptides (rather than requiring external opioids) strengthens the case for device-based pain management. The frequency-specific peptide release patterns echo classic acupuncture research, where different stimulation frequencies were also found to release different endorphins.
Questions still open
- Can these frequency-specific opioid mechanisms be confirmed in human spinal cord stimulation patients using cerebrospinal fluid sampling?
- Would alternating between frequencies during treatment sessions engage multiple opioid pathways and provide superior pain relief?
- Does long-term SCS (weeks to months) maintain its ability to release endogenous opioid peptides without developing tolerance?
Common questions
How does spinal cord stimulation relieve pain without drugs?
Does the body develop tolerance to spinal cord stimulation like it does to opioid drugs?
Read the original research
Involvement of Opioid Peptides in the Analgesic Effect of Spinal Cord Stimulation in a Rat Model of Neuropathic Pain.
Neuroscience bulletin, 38(4), 403-416
Citation
Zhai, Fu-Jun; Han, Song-Ping; Song, Tian-Jia; Huo, Ran; Lan, Xing-Yu; Zhang, Rong; Han, Ji-Sheng. (2022). Involvement of Opioid Peptides in the Analgesic Effect of Spinal Cord Stimulation in a Rat Model of Neuropathic Pain.. Neuroscience bulletin, 38(4), 403-416. https://doi.org/10.1007/s12264-022-00844-7